Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$3.50 target on Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) following publication of the company’s TIGRIS septic shock study in The Lancet Respiratory Medicine. In a March 24 note, Uddin described the data as exceptionally strong after Spectral announced full […]
Research Capital analyst Andre Uddin has raised his price target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD) to $8.55 from $8.00, while maintaining a “Buy” rating, citing stronger-than-expected fourth-quarter results and improving visibility on growth from new product launches. In a March 19 report, Uddin said Knight’s recent portfolio-building efforts […]
Share
Tweet
Share
